Status:
COMPLETED
Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.
Lead Sponsor:
Alberta Health services
Conditions:
Thyroid Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will...
Detailed Description
Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will...
Eligibility Criteria
Inclusion
- resected well-differentiated throid cancer with at least one high risk feature for locoregional recurrence
Exclusion
- medullary or anaplastic thyroid cancer, unresectable
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2010
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00279721
Start Date
January 1 2006
End Date
June 1 2010
Last Update
January 19 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.